Cure Lab is a biotechnology company committed to the development of effective vaccines against infectious diseases and cancer.

Cure Lab is intensively focusing on development of vaccines against influenza due to the threat of an impending pandemic.

The first in the pipeline of Cure Lab's anti-influenza T-cell vaccines (CLVax 1.0) has demonstrated protection against a wide variety of both mammalian and avian influenza (flu) strains when tested in rodent and chicken models.

Cure Lab, Inc. is a private biotechnology company founded in 2002.